Treatment Details – 12.1 months
|Patients: This Phase III study involved a total of 448 patients with malignant pleural mesothelioma. Patients were divided into two groups. Group A was comprised of 226 patients and Group B was comprised of 222 patients.|
Treatment: Patients in Group A received two chemotherapy drugs, pemetrexed and cisplatin (platinol). In addition, most patients were supplemented with folic acid and vitamin B12.
Toxicity: Fourteen patients in Group A died while on the study or within 30 days of the last dose of the study drugs. Three deaths were thought to be possibly related to the drugs. (These deaths occurred before folic acid and vitamin B12 supplementation was initiated.) Other toxicities included grade 3-4 hematologic, nausea, fatigue, vomiting, diarrhea, dehydration, stomatitis, anorexia, febrile neutropenia, infection, and rash.
Results: Median survival for patients in Group A was 12.1 months. (Median survival was 13.3 months for those patients who were fully supplemented with folic acid and vitamin B12).
Support: The study was supported by a grant from Eli Lilly and Company. Eli Lilly markets pemetrexed.
Correspondence: Nicholas J. Vogelzang, MD